This is a federal contract award to Emory University, a private research institution in Atlanta, Georgia, by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). The contract, valued at $1,056,666.00, is for a task order under an existing Indefinite Delivery Contract (IDC) held by Emory with NIAID. This IDC, with a ceiling value of $146,300,000 and a performance period through July 2031, enables Emory to provide NIAID with the...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a delivery order to Emory University, a private research university located in Atlanta, Georgia, for $599,404.00. The order has a period of performance from September 14, 2020 to March 20, 2023 and is not associated with a set-aside. The order falls under the DAIT/BIOD contract vehicle. Emory University has experience providing clinical trial services, data...
This federal contract award to Emory University is a Delivery Order under the National Institutes of Health (NIH) Task Order Contract, known as "NIH TCF TASK B-1." The award does not have a set-aside designation. Emory University, a private research university located in Atlanta, Georgia, is the prime contractor for this $733,849.00 cost-reimbursement contract to provide services to the National Institute of Allergy and Infectious Diseases, a component of the U.S. Department of...
This is a federal contract award to Emory University, a private research institution in Atlanta, Georgia. The contract, valued at $10,564,646.55, is a delivery order under the Vaccine and Treatment Evaluation Units (VTEU) Indefinite Delivery Contract with the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services. The contract supports Emory's research and services related to the VTEU program, which focuses on the...
Emory University, a private research institution in Atlanta, Georgia, was awarded a $79,299,221 Definitive Contract from the National Institute of Allergy and Infectious Diseases (NIAID) to serve as a Center of Excellence for Influenza Research and Response (CEIRR). The contract has a period of performance through January 14, 2027 and does not have a set-aside designation. Emory is serving as the prime contractor on this award, with several universities - including the University of Kentucky,...
<p>The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $879,633 cost no fee delivery order contract to Emory University Office Of Sponsored Programs Division for TASK ORDER B-4 covering the period from August 1, 2022 through March 20, 2027. The contract supports the National Interest Action Code of Coronavirus COVID-19. Performance will take place in Atlanta, Georgia.</p>
This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Emory University, a private university and research institution located in Atlanta, Georgia. The contract is part of the Vaccine and Treatment Evaluation Units (VTEU) program, which focuses on the development and evaluation of vaccines and treatments for infectious diseases.
The contract has a total potential value of $263,956.53 and a period of performance ending on...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Emory University, a private research institution in Atlanta, Georgia. The contract, valued at $17,242,506.00, is for the NIH TCF BASE YEAR 1 TASK A-1 project, which runs from March 21, 2020, to March 20, 2021, with a potential completion date of March 20, 2027.
The contract is a Delivery Order under a larger Indefinite Delivery...
This is a $245,000 firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Emory University, a private research institution in Atlanta, Georgia. The contract, titled "EMORY-SARS COV2 CRYIEM," is for research and services related to the COVID-19 virus. The contract has an ultimate completion date of August 30, 2024. Emory University is a major recipient of federal contracts and grants, particularly in the areas of biomedical...
Emory University was awarded a $749,998.20 definitive, firm-fixed price contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to develop "FLUVID," an innovative dry powder, inhaled, mRNA-based treatment for both influenza and COVID-19. The contract, which does not have a set-aside designation, has a performance period ending on March 31, 2026. This project showcases Emory's expertise in addressing urgent public health needs...
This federal contract award was made by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Emory University to conduct research and development on the antiviral drug EIDD-2801. The contract has a potential value of $1,108,746.46 and runs from September 9, 2019 through July 31, 2020. The contract is a definitive contract with cost reimbursement pricing and does not have a set-aside designation.
Emory University, a private non-profit research university, serves as the prime contractor. Major subcontractors include Charles River Laboratories, The Gnomon Group LLC, and Inotiv Inc., which are providing preclinical, toxicology, and other services to support the EIDD-2801 development effort. This contract appears to be part of the federal government's broader response to the Coronavirus COVID-19 pandemic, as indicated by the "National Interest Action Code: Coronavirus COVID-19" associated with the award.